menu search

ORTX / Wall Street Analysts Think Orchard Therapeutics PLC Sponsored ADR (ORTX) Could Surge 365.03%: Read This Before Placing a Bet

Wall Street Analysts Think Orchard Therapeutics PLC Sponsored ADR (ORTX) Could Surge 365.03%: Read This Before Placing a Bet
The consensus price target hints at a 365% upside potential for Orchard Therapeutics PLC Sponsored ADR (ORTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Read More
Posted: Aug 15 2023, 15:27
Author Name: Zacks Investment Research
Views: 112696

ORTX News  

Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin

By Zacks Investment Research
October 6, 2023

Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin

Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction val more_horizontal

Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains?

By Zacks Investment Research
October 6, 2023

Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains?

Orchard Therapeutics PLC Sponsored ADR (ORTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimat more_horizontal

Why Orchard Therapeutics Stock Is Soaring Today

By The Motley Fool
October 5, 2023

Why Orchard Therapeutics Stock Is Soaring Today

Orchard Therapeutics, a small-cap gene therapy company, landed a premium-rich buyout offer from Kyowa Kirin today. With biotech valuations under press more_horizontal

Orchard Therapeutics is being bought at a massive premium

By Invezz
October 5, 2023

Orchard Therapeutics is being bought at a massive premium

Shares of Orchard Therapeutics (NASDAQ: ORTX) almost doubled this morning after Kyowa Kirin Co Ltd (TYO: 4151) announced plans of buying the gene ther more_horizontal

Orchard Therapeutics shares double following Japanese bid approach

By Proactive Investors
October 5, 2023

Orchard Therapeutics shares double following Japanese bid approach

Shares of Orchard Therapeutics doubled in pre-market trading following the announcement that Japan-based pharmaceutical company Kyowa Kirin will acqui more_horizontal

Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?

By Zacks Investment Research
September 20, 2023

Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?

Orchard Therapeutics PLC Sponsored ADR (ORTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnin more_horizontal

Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up

By Zacks Investment Research
September 19, 2023

Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up

Orchard's (ORTX) regulatory filing for OTL-200, in the treatment of pediatric patients suffering from metachromatic leukodystrophy, gets FDA acceptanc more_horizontal

Orchard Therapeutics: A Reassessment

By Seeking Alpha
September 18, 2023

Orchard Therapeutics: A Reassessment

Orchard Therapeutics plc is a London-based biotech company focused on developing gene therapies for rare diseases. The company's lead therapy, OTL-200 more_horizontal


Search within

Pages Search Results: